News

Investor's Business Daily on MSN2d

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.
PharmExec16h

Novo Nordisk Implements Hiring Freeze for Non-Business Critical Roles: Report

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.
GlobalData on MSN20h

Madrigal wins European MASH approval as Novo rivalry looms

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
pharmaphorum2d

Novo Nordisk claims first GLP-1 approval in MASH

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...
Medscape2d

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Novo Nordisk stock soar 5% today: here’s why analysts are bullish

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...